News | February 23, 2022
Agilent posts Q1 FY2022 revenue at US$ 1.67 billion
Revenue of $1.67 billion represents 8% reported growth; and up 9% on a core(basis.
Revenue of $1.67 billion represents 8% reported growth; and up 9% on a core(basis.
US $ 555,000 invested by Wavemaker Partners in pre-seed round
Dr. Reddy’s, will focus its resources and capabilities on its key therapy spaces of gastroenterology, pain management, cold and flu, allergy, oncology, neurology, paediatrics and women’s health as the Russia and CIS region continues to be a strong performer for the company
By connecting a leading LongBio VC to the DeSci (decentralized science) movement, this partnership is a major milestone for the greater decentralized ecosystem
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
Recall does not include any metabolic deficiency nutrition formulas
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
Subscribe To Our Newsletter & Stay Updated
